Datasets Discovered: Addition of New NGS Model Datasets

Nov 24, 2021 11:48:39 AM / by Champions Oncology posted in Lumin Bioinformatics

Importance of the Dataset

Champions’ PDX and Hematological models are well-characterized and include patient clinical attributes, disease status, treatment history and in vivo drug responses to a range of Standard of Care therapies. New NGS datasets spanning across various indications, have been recently added to our software platform, Lumin Bioinformatics, specifically 114 model datasets of RNA-Seq and 148 model datasets of WES. Below, we illustrate the model disease types that have been added to Lumin Bioinformatics that have both RNA-Seq and WES datasets. In particular, additional Acute Lymphoblastic Leukemia (ALL) models are currently available for research on our Hematological Screen. Additionally, a large cohort of Sarcoma, Colorectal, and Head & Neck Cancer model datasets have been incorporated into Lumin Bioinformatics. Champions also adds to its Glioblastoma model datasets with the 11 datasets included in this update to our platform.

Read More →

Non-Small Cell Lung Cancer: Developments in Targeted Therapies

Nov 17, 2021 11:00:00 AM / by Champions Oncology posted in Solid Tumor Oncology

Lung cancer remains one of the leading causes of cancer-related deaths, and non-small cell lung cancer (NSCLC) is the most common form of lung cancer and is typically diagnosed at advanced stages[1]. Extensive genomic studies of NSCLC have been essential to identifying mutations that drive oncogenesis and has been critical to the development of targeted therapies. Here we highlight progress in NSCLC treatment and identify areas of ongoing research.

Read More →

Advances in Pancreatic Cancer: A Multi-Omics Driven Approach

Nov 11, 2021 11:00:00 AM / by Champions Oncology posted in Solid Tumor Oncology

Pancreatic ductal adenocarcinoma (PDAC) is one of the most common and aggressive forms of pancreatic cancer that has remained difficult to diagnose early and treat successfully. PDAC has a five-year survival rate below 10% and is one of the leading causes of cancer death. Complete surgical resection is one of the few curative treatment modalities, and chemotherapy protocols have limited efficacy[1]. Unfortunately, most existing immunotherapy-based treatments are also associated with poor response rates[2]. Recent analyses of PDAC samples have provided critical insights into genetic alterations that drive tumorigenesis and have identified potential therapeutic targets. Here we highlight several of these key findings and how they may lead to advances in PDAC treatment.

Read More →

Choosing the RIGHT Model - Syngeneic versus Humanized Mouse Models

Nov 4, 2021 11:00:00 AM / by Champions Oncology posted in Syngeneic Models, Immuno-Oncology, Humanized Models

Mouse models have been the workhorses of preclinical immuno-oncology (IO) research, and advances in mouse model development have expanded to applications for nearly all types of solid tumors and hematological malignancies. Preclinical evaluation of experimental immunotherapies has been advanced by syngeneic and humanized mouse models. Syngeneic mice are one of the most established types of models used in cancer research, whereas humanized mice are contemporary mouse model that has been critical to the screening of immunotherapeutic agents. Here we highlight features of syngeneic and humanized mouse models and define which models are most relevant to different phases of preclinical IO research.

 

Read More →

New Therapies for Targeting HER2

Oct 28, 2021 11:00:00 AM / by Champions Oncology posted in Solid Tumor Oncology

Human epidermal growth factor receptor 2 (HER2; ERBB2) has been shown to induce oncogenesis in several cancers, particularly breast and gastric cancers. HER2 is estimated to be overexpressed in ~20% of all breast cancers, and outcomes for these breast cancers were poor before HER2-targeted therapies[1]. Our understanding of mechanisms by which HER2 drives tumor growth and metastasis led to one of the first targeted therapies for treating HER2+ breast cancers. Here we highlight what is known about HER2 and oncogenesis. and how this information can be applied to the development of new targeted therapies.

Read More →

Obesity and Hepatocellular Carcinoma

Oct 21, 2021 11:00:00 AM / by Champions Oncology posted in Solid Tumor Oncology

Obesity has been linked to numerous comorbidities, including insulin resistance, type 2 diabetes, chronic inflammation, and hepatocellular carcinoma (HCC). Non-alcoholic fatty liver disease (NAFLD) is an obesity comorbidity that is closely linked to the development of HCC and is independent of other HCC risk factors like chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or heavy alcohol consumption[1]. HCC is one of the leading causes of cancer and cancer-related deaths, especially in men, and here we highlight current research linking obesity and lifestyle choices to HCC.

Read More →

Novel RNAs Insights Toward AML Development

Oct 7, 2021 11:00:00 AM / by Champions Oncology posted in Hematological Malignancies


Somatic mutations in the additional sex comb-like 1 (ASXL1) gene have been identified in multiple hematologic malignancies, including acute myeloid leukemia (AML), and are associated with poor prognoses1. ASXL1 encodes a nuclear protein that regulates epigenetic remodeling and transcription through interactions with polycomb complex proteins and transcriptional activators and repressors. Several ASXL1 mutations have been associated with loss of protein expression that leads to myeloid transformation2. In contrast, gain-of-function mutations in ASXL1 result in expression of a truncated ASXL1 protein that can bind to BRCA-1 associated protein 1 (BAP1) and cause leukemogenesis3,4. Targeted reduction of BAP1 activity is sufficient to prevent this malignancy process5.

Read More →

UnTIL We Meet Again: Testing TIL Therapies in an Ex Vivo Platform

Sep 30, 2021 11:00:00 AM / by Champions Oncology posted in Immuno-Oncology, Ex Vivo Platforms

Tumor infiltrating lymphocyte (TIL)-based immunotherapy is currently at the forefront of cutting-edge immuno-oncology treatments. TILs are a type of adoptive cellular therapy (ACT) using lymphocytes that are found within tumor tissues; most of these lymphocytes are T cells that can specifically target tumor cells. For TIL-based therapies, these T cells are harvested from a tumor biopsy, expanded ex vivo, and infused back into the patient. Advances in TIL-based therapies are driven by preclinical characterization and screening of TILs against a wide array of tumor types.

Read More →

Prostate Cancer: Drivers of Genetic Mutations & Their Role in Disease Progression

Sep 16, 2021 11:00:00 AM / by Champions Oncology posted in Solid Tumor Oncology

Prostate cancer is one of the most common forms of cancer that affects the prostate gland in the male urogenital tract. Most prostate cancers are slow growing and are detected in individuals older than age 50. Although environmental factors contribute to the development of prostate cancer, risk is significantly associated with incidence among first-degree relatives. In recent years, several inherited and spontaneously mutated genes have been linked to prostate cancer. Here we highlight these findings and how they provide insight into the development of targeted prostate cancer therapies.

Read More →

Datasets Discovered: DLBCL Cohort

Sep 15, 2021 11:00:00 AM / by Champions Oncology posted in Lumin Bioinformatics

Importance of the Dataset

Diffuse Large B-Cell Lymphoma (DLBCL) is a cancer of the B cells and is the most common form of non-Hodgkin’s Lymphoma (NHL) among adults. Champions’ DLBCL models encompass various subtypes of the disease, including ABC (Activated B cell), GCB (Germinal Center B cell), and Richter. These models are well-characterized and include patient clinical attributes, disease status, treatment history and in vivo drug responses to a range of therapies, including CHOP or a Rituximab-CHOP (R-CHOP) combination treatment. Champions DLBCL model cohort includes diverse molecular features such as double and triple hit mutations, as well as mutations in several key pathways such as proliferation, oncogenic signaling, and B cell differentiation. This unique dataset includes next generation sequencing (NGS), proteomics and phospho-proteomics from Champions’ DLBCL cohort.

Read More →
Content not found